Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL

NCT02572453 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02572453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02572453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of the Heat Shock Protein-90 (Hsp90) Inhibitor AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ ALCL, Mantle Cell Lymphoma, and BCL6+ DLBCL
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
April 4, 2016
Completion date
March 18, 2021
Enrollment
25 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent anaplastic large cell lymphoma, recurrent diffuse large b-cell lymphoma, recurrent mantle cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory anaplastic large cell lymphoma, refractory diffuse large b-cell lymphoma, refractory mantle cell lymphoma, refractory transformed non-hodgkin lymphoma